• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.

    2/6/26 6:43:06 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    CalciMedica Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    38942Q202

    (CUSIP Number)


    02/06/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    38942Q202


    1Names of Reporting Persons

    Deerfield Mgmt, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    653,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    653,253.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    653,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.34 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Comprised of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable) held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.


    SCHEDULE 13G

    CUSIP No.
    38942Q202


    1Names of Reporting Persons

    Deerfield Management Company, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    653,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    653,253.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    653,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.34 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Consists of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable) held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.


    SCHEDULE 13G

    CUSIP No.
    38942Q202


    1Names of Reporting Persons

    Deerfield Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    653,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    653,253.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    653,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.34 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Consists of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable).


    SCHEDULE 13G

    CUSIP No.
    38942Q202


    1Names of Reporting Persons

    James E. Flynn
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    653,253.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    653,253.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    653,253.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.34 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Consists of 653,253 shares of Common Stock issuable upon exercise of warrants (subject to any adjustments that may be applicable) held by Deerfield Partners, L.P.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CalciMedica Inc.
    (b)Address of issuer's principal executive offices:

    505 Coast Boulevard South, Suite 307, La Jolla, CA 92037
    Item 2. 
    (a)Name of person filing:

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P.
    (b)Address or principal business office or, if none, residence:

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
    (c)Citizenship:

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn - United States citizen
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    38942Q202
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Deerfield Mgmt, L.P. - 653,253 shares Deerfield Management Company, L.P. - 653,253 shares Deerfield Partners, L.P. - 653,253 shares James E. Flynn - 653,253 shares
    (b)Percent of class:

    Deerfield Mgmt, L.P. - 4.34% Deerfield Management Company, L.P. - 4.34% Deerfield Partners, L.P. - 4.34% James E. Flynn - 4.34%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    All Reporting Persons - 0

     (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 653,253 Deerfield Management Company, L.P. - 653,253 Deerfield Partners, L.P. - 653,253 James E. Flynn - 653,253

     (iii) Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 653,253 Deerfield Management Company, L.P. - 653,253 Deerfield Partners, L.P. - 653,253 James E. Flynn - 653,253

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit B
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Deerfield Mgmt, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:02/06/2026
     
    Deerfield Management Company, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:02/06/2026
     
    Deerfield Partners, L.P.
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:02/06/2026
     
    James E. Flynn
     
    Signature:/s/ Jonathan Isler
    Name/Title:Jonathan Isler, Attorney-In-Fact
    Date:02/06/2026
    Exhibit Information

    Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

    Get the next $CALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CALC

    DatePrice TargetRatingAnalyst
    1/29/2026Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $CALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CalciMedica downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CalciMedica from Buy to Neutral

    1/29/26 7:00:08 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.

    SCHEDULE 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    2/6/26 6:43:06 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by CalciMedica Inc.

    8-K - CalciMedica, Inc. (0001534133) (Filer)

    1/28/26 5:28:57 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - CalciMedica, Inc. (0001534133) (Filer)

    1/28/26 7:06:11 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,675 worth of shares (2,500 units at $3.07) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/22/25 9:35:04 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $9,105 worth of shares (3,400 units at $2.68) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/17/25 9:45:05 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $15,600 worth of shares (5,000 units at $3.12) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/15/25 12:31:52 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

    Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), a population char

    1/28/26 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026 Cash position expected to fund operations into 2H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2025

    11/12/25 7:01:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

    Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing treatments Cardiac benefit supports the mechanistic rationale for CRAC channel inhibition in acute kidney injury (AKI), being evaluated in the Phase 2 KOURAGE trial with data expected in 1H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immun

    11/12/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Glicklich Alan

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    10/14/25 12:22:17 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,675 worth of shares (2,500 units at $3.07) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/22/25 9:35:04 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $9,105 worth of shares (3,400 units at $2.68) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/17/25 9:45:05 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by CalciMedica Inc.

    SC 13D - CalciMedica, Inc. (0001534133) (Subject)

    11/26/24 6:03:55 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 3:32:39 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CalciMedica Inc.

    SC 13G/A - CalciMedica, Inc. (0001534133) (Subject)

    11/14/24 1:05:20 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Leadership Updates

    Live Leadership Updates

    View All

    CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, including a post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia, which showed a 62.7% relative reduction in mortality for Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., May 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    5/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

    Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition

    3/27/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

    LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.

    1/14/25 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CALC
    Financials

    Live finance-specific insights

    View All

    CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

    Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT LA JOL

    10/30/24 7:00:00 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

    Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT LA JOLLA, Calif., Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m. ET/ 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). Prof. Robert Sutt

    10/28/24 4:05:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

    Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif., Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica or the Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024.

    8/12/24 4:10:00 PM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care